Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease

This study is collecting real-world data on patients with inflammatory bowel disease — either ulcerative colitis or Crohn's disease — who are starting treatment with a medication called upadacitinib (a JAK inhibitor). Researchers want to track how well the drug works and what side effects occur in everyday clinical practice, outside of a controlled trial setting. **You may be eligible if...** - You have been diagnosed with ulcerative colitis or Crohn's disease based on current medical guidelines - Your doctor has decided that upadacitinib is the appropriate first treatment with this drug for your condition - You are able and willing to provide signed informed consent - You are of any gender **You may NOT be eligible if...** - You are currently participating in another clinical trial - You have a medical reason that makes upadacitinib unsafe for you (as per the drug's prescribing information) - Your treating doctor has assessed you as unsuitable for the study Talk to your doctor to see if this trial is right for you.